SCHEMBL7189654

SCHEMBL7189654

C=CCN(CC(=O)Oc1ccc(C(=N)N)cc1)C(=O)/C(C)=C/c1ccc(C(=O)Oc2ccc(C(=N)N)cc2)cc1

nearest known ligand 0.88

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 16/20 0.88
F2 P00734 4/20 0.88
KLK1 P06870 4/20 0.88
TMPRSS15 P98073 14/20 0.46
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HSP90AA1 P07900 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189652 1.00 PRSS1 (0.88) PRSS1F2KLK1TMPRSS15KDM4E
SCHEMBL7311244 0.93 PRSS1 (1.00) PRSS1F2KLK1TMPRSS15KDM4E
SCHEMBL3245051 0.93 PRSS1 (1.00) PRSS1F2KLK1TMPRSS15KDM4E
SCHEMBL7309079 0.93 PRSS1 (0.81) PRSS1F2KLK1TMPRSS15
SCHEMBL7191629 0.92 PRSS1 (0.85) PRSS1F2KLK1TMPRSS15KDM4E
SCHEMBL7191624 0.92 PRSS1 (0.85) PRSS1F2KLK1TMPRSS15KDM4E
SCHEMBL3238554 0.92 PRSS1 (1.00) PRSS1F2KLK1TMPRSS15
SCHEMBL7314190 0.92 PRSS1 (1.00) PRSS1F2KLK1TMPRSS15
Acetic Acid SCHEMBL7312877 0.92 PRSS1 (0.96) PRSS1F2KLK1TMPRSS15KDM4E
Acetic Acid SCHEMBL7311943 0.92 PRSS1 (0.96) PRSS1F2KLK1TMPRSS15KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6583177-B2 Amidinophenol derivatives as leukotriene B4 (LTB4)antagonists, phospholipase A2 inhibitors, and trypsin inhibitors. ONO PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 US claimed
US-20020128315-A1 Leukotriene B4 antagonist compounds and method for treatment NAKAI HISAO (JP) 2002-09-12 US claimed
US-6262114-B1 NOVEL AMIDINOPHENOL DERIVATIVES; INHIBITORS OF PHOSPHOLIPASE A2 AND/OR TRYPSIN ONO PHARMACEUTICAL CO., LTD. (JP) 2001-07-17 US claimed
EP-0703216-B1 Amidinophenol derivatives as protease inhibitors ONO PHARMACEUTICAL CO (JP) 1999-04-07 EP claimed
EP-0703216-A1 Amidinophenol derivatives as protease inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1996-03-27 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128315-A1 Leukotriene B4 antagonist compounds and method for treatment LTB4R2, LTB4R, LTA4H PRSS1 146/4885F2 182/4885KLK1 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.